## SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [**REDACTED**] and without taking into account any H Shares which may be issued pursuant to the exercise of the [**REDACTED**], the following person will have an interest or short position in the H Shares or underlying Shares which will be required to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company or any of our subsidiaries:

| | | As of the Latest Practicable Date(1) | | Immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised)(1) | |
|---|---|---|---|---|---|
| **Name of Shareholder** | **Capacity/Nature of interest** | **Number of Shares** | **Approximate percentage of interest in our Company** | **Number of H Shares** | **Approximate percentage of interest in our Company** |
| Ms. Cheong | Interested in controlled corporation(2) | 14,959,232(L) | 46.63% | [REDACTED] | [REDACTED] |
| Renxiang Biotechnology | Interested in controlled corporation(2) | 14,959,232(L) | 46.63% | [REDACTED] | [REDACTED] |
| China True Health Medical | Interested in controlled corporation(3) | 8,760,000(L) | 27.30% | [REDACTED] | [REDACTED] |
| Renyang Biotechnology | Beneficial interest(2 & 3) | 3,360,000(L) | 10.47% | [REDACTED] | [REDACTED] |
| Chengzhen Health | Beneficial interest(2 & 3) | 3,000,000(L) | 9.35% | [REDACTED] | [REDACTED] |
| Guangdong-Macao Cooperation & Development Fund (廣東粵澳合作發展基金(有限合夥)) ("**Guangdong-Macao Development Fund**") | Interested in controlled corporation(4) | 2,877,337(L) | 8.97% | [REDACTED] | [REDACTED] |
| Hengqin Guangdong-Macao Development & Investment Co., Ltd.* (橫琴粵澳開發投資有限公司) ("**Guangdong-Macao Investment**") | Beneficial interest(4) | 2,877,337(L) | 8.97% | [REDACTED] | [REDACTED] |
| Jiarun Tongchuang | Beneficial interest(2 & 3) | 2,400,000(L) | 7.48% | [REDACTED] | [REDACTED] |
| China International Capital Corporation Limited (中國國際金融股份有限公司) ("**CICC**") | Interested in controlled corporation(5) | 2,014,137 (L) | 6.28% | [REDACTED] | [REDACTED] |
| Shuimu Medical Technology | Interested in controlled corporation(6) | 2,293,900(L) | 7.15% | [REDACTED] | [REDACTED] |
| Jiarun Hechuang | Beneficial interest(2 & 6) | 2,293,900(L) | 7.15% | [REDACTED] | [REDACTED] |
| Zhuhai Meijirui | Beneficial interest(2) | 2,071,682(L) | 6.46% | [REDACTED] | [REDACTED] |

*Notes:*

1. The letter "L" denotes the entity/person's long position (as defined under Part XV of the SFO) in such Shares.

2. As of the Latest Practicable Date, Renxiang Biotechnology is the general partner of each of Renyang Biotechnology, Chengzhen Health, Jiarun Tongchuang, Jiarun Hechuang, Zhuhai Meijirui, Jiarun Xinchuang and Xinhui Runkang and Renxiang Biotechnology is held as to 99.99% by Ms. Cheong and 0.01% by Ms. Yu Lili (于莉莉). As such, each of Ms. Cheong and Renxiang Biotechnology is deemed to be interested in the Shares held by Renyang Biotechnology, Chengzhen Health, Jiarun Tongchuang, Jiarun Hechuang, Zhuhai Meijirui, Jiarun Xinchuang and Xinhui Runkang under the SFO.

3. As of the Latest Practicable Date, Renyang Biotechnology, Chengzhen Health and Jiarun Tongchuang were owned as to 99% by China True Health Medical as their sole limited partner. As such, China True Health Medical is deemed to be interested in the Shares held by Renyang Biotechnology, Chengzhen Health and Jiarun Tongchuang under the SFO.

4. As of the Latest Practicable Date, Guangdong-Macao Investment was owned as to 50% by Guangdong-Macao Development Fund. As such, Guangdong-Macao Development Fund is deemed to be interested in the Shares held by Guangdong-Macao Investment under the SFO.

5. As of the Latest Practicable Date, our Company was owned as to 1.35%, 0.45% and 4.48% by Huzhou CICC Qihe Equity Investment Partnership (Limited Partnership)* (湖州中金啟合股權投資合夥企業(有限合夥)) ("**CICC Qihe**"), Dongrong No. 1 (Zhuhai Hengqin) Equity Investment Partnership (Limited Partnership)* (東融壹號(珠海橫琴)股權投資合夥企業(有限合夥)) ("**Dongrong No. 1**") and Hengqin Guangdong Macao Deep Cooperation Zone Industrial Investment Fund (Limited Partnership)* (橫琴粵澳深度合作區產業投資基金(有限合夥)) ("**Hengqin Industrial**"), respectively. As of the Latest Practicable Date, (i) CICC Private Equity Management Co., Ltd.* (中金私募股權投資管理有限公司), a wholly-owned subsidiary of CICC, is the general partner of CICC Qihe; (ii) CICC Capital Management Co., Ltd.* (中金資本運營有限公司) ("**CICC Capital**"), a wholly-owned subsidiary of CICC, is the general partner of Dongrong No. 1; and (iii) CICC Capital is the general partner of Hengqin Industrial. As such, CICC is deemed to be interested in the Shares held by CICC Qihe, Dongrong No. 1 and Hengqin Industrial under the SFO.

6. As of the Latest Practicable Date, Jiarun Hechuang was owned as to 99% by Shuimu Medical Technology as its sole limited partner. As such, Shuimu Medical Technology is deemed to be interested in the Shares held by Jiarun Hechuang under the SFO.

Save as disclosed herein, our Directors are not aware of any persons who will, immediately following the completion of the [**REDACTED**] and without taking into account any H Shares which may be issued pursuant to the exercise of the [**REDACTED**], have an interest or short position in the Shares or underlying Shares which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company or any other member of our Group. Our Directors are not aware of any arrangement which may at a subsequent date result in a change of control of our Company.